Aims: As low rates of thiamine are thought to be implicated in alcohol-related cognitive disorders, we wanted to assess patients with alcohol use disorders (AUD) during detoxification for their nutritional status and test if vitamins blood levels were associated with a surrogate of cognitive impairment. Methods: We performed a retrospective chart review of medical records of 94 consecutive patients hospitalized for alcohol detoxification in a specialized addiction medicine department. Nutritional status was assessed with Body Mass Index (BMI). Vitamins blood levels were available for 80 patients, but thiamine only for 52 patients. The Montreal Cognitive Assessment (MoCA) score was used to screen for cognitive impairment at Day 10 of entry and was available in 59 patients. A binary logistic regression was performed to identify factors associated with MoCA scores below the threshold (26 points). Results: The mean BMI was 23.28 ± 3.78 kg/m 2 and 8.79% of weighted patients qualified for malnutrition. The mean MoCA score was 22.75 ± 4.88 points, and 66% of tested patients were below the threshold of suspected cognitive impairment. No low blood thiamine level was found. In multivariate analysis, BMI, but not vitamins blood rates, was significantly associated with a pathological MoCA screening test. Conclusion: Clinical examination is more sensitive than biomarkers to determine malnourished AUD patients who are at-risk for cognitive impairment. Malnourished patients with AUD should receive a full neuropsychological testing. Summary: This retrospective chart review study screened for cognitive disorders during alcohol inpatient detoxification with the MoCA test. Body mass index, but not vitamins blood rates, was associated with a pathological MoCA. Clinical examination is more sensitive than biomarkers to determine malnourished AUD patients who are at-risk for cognitive impairment.
INTRODUCTION
The scientific literature reports high rates of dementia in patients with alcohol use disorders (AUD), up to 24% when all types of severe cognitive impairment are considered (Ridley et al., 2013) . Previously, two main disorders were described: Wernicke-Korsakoff syndrome (WKS) and alcohol-related dementia (ARD) (Ridley et al., 2013) . Now, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders introduces major neurocognitive disorder as an alternative term to dementia, with a subtype related to substance and/or medication use (Sachdev et al., 2014) . WKS and ARD could be a direct result of alcohol neurotoxicity, or the consequence of a co-occurring underlying pathology (such as thiamine deficiency) or both (neurotoxicity associated with nutritional deficiencies) (Ridley et al., 2013 ). Wernicke's encephalopathy (WE), which can lead to WKS, seems to be underdiagnosed, with a higher prevalence of WE lesions in autopsy studies (0.8-2.8%) than predicted in clinical studies (0.04-0.13%) (Sechi and Serra, 2007) . But major neurocognitive disorder is now regarded as the emerged part on the iceberg, the final stage of a long lasting continuous process at work in patients with AUD who display several dimensions of cognitive impairment several years before the diagnosis of major neurocognitive disorder (Brion et al., 2014) .
Even mild alcohol-related cognitive disorders that do not qualify for a severe neurocognitive disorder diagnosis have an impact on daily functioning and treatment access. Indeed, the behavioral changes in alcohol habits needed to reach and maintain abstinence or low-risk alcohol consumption are more difficult to achieve in individuals with alcohol-related cognitive impairment, and far more difficult in those who qualify for ARD. Patients with ARD display several alterations in cognitive functions, such as a decrease in information processing speed, or dysexecutive syndrome associating flexibility, inhibition, planning, manipulation in working memory and conceptualization alterations (Vabret et al., 2016) . ARD is poorly identified and treated, partly because of frequent social isolation suffered by patients with AUD. This is why it seems important to screen and identify those patients as early as possible, for example, if they are hospitalized (Ridley et al., 2013) . In order to enhance diagnosis, the classic triad of clinical criteria for Wernicke's encephalopathy (oculomotor abnormalities, cerebellar dysfunction and either altered mental state or mild memory impairment), was modified to include the presence of dietary deficiencies. The clinical diagnosis requires now two signs instead of three (Caine et al., 1997) . Several tools are also developed to screen for cognitive impairment in patients with AUD even before a full neuropsychological testing procedure can be performed, such as the Montreal Cognitive Assessment (MoCA) test (Copersino et al., 2009; Alarcon et al., 2015) . In patients with Substance Use Disorders, the MoCA is thought to be more sensitive than the MMSE (Folstein et al., 1975) because it has items testing executive functions, especially a short trail making test and a clock drawing test. The main objective of this study was to assess nutritional and cognitive status in patients hospitalized in an addictology-oriented internal medicine ward for alcohol withdrawal. The secondary objective of this study was to determine whether there was a relationship between nutritional status and cognitive impairment in those patients.
MATERIAL AND METHODS

Subjects
Inpatients consecutively admitted to the Addiction Medicine Department of the Lariboisière-Saint-Louis-Fernand Widal Hospital Group in Paris were included. They were hospitalized for scheduled alcohol detoxification or for unscheduled alcohol detoxification during the course of another medical condition (seizure, pancreatitis, HIV infection, etc.) (Azuar et al., 2016) . Patients whose reason for hospitalization was withdrawal from another substance, and patients with decompensated cirrhosis (Child B or C) were excluded. We also excluded patients who had already been hospitalized less than 3 months ago (considering that a possible malnutrition would have been treated with appropriate feeding and nutrients and vitamins supplementation).
Data collection
Patients were weighed and measured within 1 week of admission. The Body Mass Index (BMI) was calculated as weight in kilogram divided by the height in meters (squared). Blood determinations were made on the day of arrival. Data that describe nutritional status: albumin, prealbumin, calcium, phosphorus, magnesium, C reactive protein (CRP), vitamin B1 (diphosphorylated thiamine), B6 (pyridoxal 5'P erythrocyte), A (retinoic acid), B3 (or PP, nicotinic acid), B12 (cobalamin), C (ascorbic acid) and D (25-hydroxycholecalciferol) were analyzed when available in patients' files. Those parameters were chosen because they reflect the general nutritional status and because some of them have been directly linked with either alcohol-related cognitive disorders, especially the B vitamins. Furthermore, some have been associated with cognitive decline in the general population, such as B9 and B12 (Reynolds, 2006) or D vitamin (Lee et al., 2009; Darwish et al., 2015) . Vitamins were assessed by the hospital laboratory with high performance liquid chromatography, except vitamin D assessed by automated chemiluminescence micro-particle immunoassay. Monophosphorylated thiamin as well as total thiamine rate were not part of this routine vitamin assessment.
For the screening of cognitive disorders, the Montreal Cognitive Assessment test (MoCA) (Copersino et al., 2009; Alarcon et al., 2015) was used at Day 10 to ensure that the assessment took place after benzodiazepine discontinuation. It was administered by a medical assistant who was blind to patients' biological nutritional status. We used a threshold of strictly <26 points to define patients at-risk of cognitive impairment.
Ethics
The study was conducted according to the Declaration of Helsinki and to the ethical guidelines of our hospital for the analysis of already collected data during routine care (authorization 2017-013 given on 19 January 2017 by the CNIL (Commission Nationale Informatique et Liberté, French national board for information systems and freedom).
Statistical analysis
The variables in the population were described by their mean, standard deviation and median. Univariate analyzes were performed to measure whether the available variables were associated with a pathological MoCA score, with khi 2 test for categorical variables (gender, types of alcohol used, observed neurological signs or symptoms at entry, percentages of patients below the normal range for nutritional parameters), and ANOVA for continuous variables (age, BMI, daily alcohol intakes, mean biological results) after normal distribution checking. The variables identified as possibly associated with a low MoCA score were integrated into a binary logistic regression (conditional descending method) model, with a P < 0.05 threshold. Because of the importance of age in the literature on cognitive disorders in general and more specifically on the MoCA score (Kenny et al., 2013) , age was also introduced into the model. All P values <0.05 were considered statistically significant. Statistical analysis was carried out using the Statistical Package for Social Sciences software, SPSS, IBM (version 21).
RESULTS
A total of 176 patients were admitted in our unit between June 15 and 24 August 2015; among them, 82 subjects were excluded.
Sample description
The remaining 94 subjects, 80 men (85%) and 14 women (15%) were aged 49.25 ± 12.05 years (median 50.5 years). They declared a daily alcohol intake of 198 ± 111 g/day . The type of alcohol consumed was documented in the medical record for 58 patients (64%). They drank beer only (N = 18, 31%), wine only (N = 15, 26%), whisky only (N = 6, 10%), vodka only (N = 3, 5%), pastis only (N = 2, 3%), rum only (N = 2, 3%) or several alcohol types (N = 12, 21%).
Patients were admitted for a scheduled alcohol cessation program after outpatient preparation visits (N = 71, 75.5%) or for unscheduled alcohol cessation, directly from the emergency room or the intensive care unit (N = 23, 24.5%) after an alcohol-related acute medical condition (Azuar et al., 2016) . Of those, 12 patients had received a documented B1 (thiamin) or B1 and B6 (thiamine and pyridoxine) vitamins supplementation during their stay. The number of scheduled patients who had received previously to their admission a B1 and B6 (thiamine and pyridoxine) vitamins supplementation prescription was six. We found no mention of patient receiving B9 (folates) or B12 prior to their hospitalization.
Nearly one third of patients had central neurologic symptoms at entry (N = 28, 30.7%), mostly ataxia (N = 23, 24.4%), delirium (N = 4, 4.2%), already known cognitive disorders (N = 2, 2.1%). Of note, no patient had presented oculomotor signs, including unscheduled patients at their first examination in the emergency room or intensive care unit. Among the 94 included patients, 18 patients had additional neurologic and/or neuropsychological tests during their inpatient stay because of those symptoms, mainly MRI (14 patients), but also contrast-agent brain imaging (2), EEG (2), EMG (2), full neuropsychological testing (2). Still, 4 patients had persistent cerebellar symptoms at discharge requiring further explorations.
Malnutrition prevalence
Measured BMI was 23.28 ± 3.78 kg/m 2 (median 22.86) (N = 91).
We observed that 8.79% of the screened patients (8/91) presented a malnutrition, defined by a low BMI (<18.5 kg/m 2 ), according to The European Society of Clinical Nutrition and Metabolism (Cederholm et al., 2015) .
Nutrition parameters and vitamins assay
The results of the biological tests describing the nutritional status are given in Table 1 .
When considering the mean scores, all biomarkers rates were in laboratory standards, except vitamins B3 (nicotinic acid) and B6 (pyridoxine) rates which were above standards.
Individually, none of the patients had low blood B1 (thiamine), B3 (nicotinic acid) or B6 (pyridoxine) vitamin levels. Twenty patients had a higher pyridoxine level than the upper limit of the laboratory standards.
On the contrary, several nutritional biomarkers were below the normal range in some patients, and the percentages are shown in Table 1 . It was the case for albumin, prealbumin, calcium, phosphorus, magnesium, A, B9 (folic acid), B12 (cobalamin), C (ascorbic acid) and D (cholecalciferol) vitamins. For this last vitamin, 29 patients (35.8%) had a mild deficit (10-20 ng/ml) and 19.75% had a severe deficit of <10 ng/ml. The percentage of patients with a high CRP level is also described.
Cognitive screening test
The results of the MoCA cognitive screening test were mean score 22.75 ± 4.88 points, median 24 points (N = 59). Of the 59 patients with available MoCA test, 66% qualified for suspected cognitive impairment (score < 26 points).
Factors associated with low MoCA score
Sex ratio was not statistically different in patients with low MoCA scores (80% males versus 82%), khi 2 = 0.037, P = 0.848, neither was age (54 ± 12, N = 39; versus 49 ± 10, N = 20) (ANOVA F = 2.47, P = 0.121).
There was also no statistical difference between the mean amount of alcohol intake between patients with pathological MoCA scores (N = 39, mean 173 ± 100 g/day) versus patients with MoCA scores ≥ 26 points (N = 19, mean 229 ± 127 g/day) (ANOVA (1df) = 3.374, P = 0.073). Furthermore, no association was observed between the type of alcohol used and low MoCA scores, although this analysis was only available in 42 patients with both documented MoCA score and type of preferred alcoholic beverage (khi 2 (6df) = 4.26, P = 0.641), even when only the comparison between spirits (N = 16) versus beer and wine (N = 26) was considered (khi 2 (1df) = 0.578, P = 0.510). The presence of neurological signs at entry (none N = 42, ataxia N = 16, and delirium N = 1) was not associated with low MoCA scores in patients with available cognitive disorder screening (N = 59), which was not performed in the two patients with already known cognitive disorder (khi 2 (2df) = 0.625, P = 0.732).
Univariate analysis with khi 2 tests did not retain any nutrition biomarker below the normal range as associated with low MoCA scores with a threshold of P < 0.05 (see Table 1 ). Among patients with documented B supplementation at entry (yes or no) and cognitive screening test (N = 9), no statistically significant association was found (khi 2 (1df) = 1.822, P = 0.253). The only value for which we observed a statistically significant difference was the BMI (22 ± 3 kg/m 2 in the low MoCA group (N = 39) versus 25.4 ± 4.6 kg/m 2 (N = 20) in the group of patients with MoCA scores above the threshold). Therefore, only BMI and age were used in the logistic regression model.
Multivariate analysis
A total of 54 patients were included in this analysis, of which 39 were defined as having pathological MoCA scores (<26 points) and 20 had normal scores ≥26. The BMI alone correctly classified 92.1% of patients with a score <26 and 36.8% of patients with a normal score (R 2 of Nagelkerke = 0.227, khi 2 (1ddl) = 10.184, P = 0.001). The addition of age slightly improved the model (Nagelkerke's R 2 = 0.264, khi 2 (2ddl) = 12.031, P = 0.002), but only on the prediction of subjects with scores ≥ 26. They were 42.1 % to be correctly classified, as were 89.5% of the subjects below the pathological threshold, which is slightly less than when BMI alone is considered. 
DISCUSSION
The aim of this study was to evaluate the nutritional and cognitive statutes of patients hospitalized for alcohol withdrawal and to determine whether there was a predictive factor for cognitive impairment in this population.
Malnutrition prevalence
We observed that 8.79% of the weighted patients (8/91) presented a malnutrition, defined by a low BMI (<18.5 kg/m 2 ), according to The European Society of Clinical Nutrition and Metabolism (Cederholm et al., 2015) . Another malnutrition definition combines the finding of unintentional weight loss (mandatory) and at least one of either reduced BMI or a low fat free mass index (FFMI) (Cederholm et al., 2015) , but FFMI assessment is not part of standard practice. Furthermore, weight loss is difficult to inform in alcohol-dependent patients, because of possible memory bias or lack of previous weight available.
The prevalence of malnutrition that we observe: 8.79% is high in a population of this age (mean: 49 years old), but lower than what is observed in other hospitalized patients with specific medical conditions, such as geriatric inpatients defined by an age above 65 years old (52%) (Buurman et al., 2011) , or internal medicine multimorbidity patients (50%) (Gomes et al., 2017) . Specifically designed nutrition programs have been proposed to reduce the impact of stays in hospital in elderly (Mudge et al., 2017) , polymorbid internal medicine patients (Gomes et al., 2017) , or during perioperative stays (Braga et al., 2009 ).
Nutrition parameters and vitamins assay
Despite the observation that close to 9% of patients qualified for the definition of malnutrition, we observed contrasted rates of specific vitamins or nutrition biomarkers. We did not observe patient below the normal values of B1 (thiamine), B3 nor B6, but observed patients with low rates of albumin (46.3%), prealmumin (50.6%), calcium (4.7%), phosphorus (13.8%), magnesium (11.1%), vitamin A (7.1%), B9 (folates) (28.7%), B12 (11%), C (53% but only performed in 10 patients), D (52%) and rates above the normal range for CRP in 30.1% of patients.
First, we have to acknowledge that in this study, no patient presented a vitamin B1 (thiamine) deficiency. This result was unexpected. It is partly explained by documented B1 (thiamine) prescription in 12 out 23 unscheduled patients directly transferred from the emergency room or the intensive care unit, and in 6 out of 71 scheduled alcohol detoxification patients. Some patients may also have received supplementation at entry before blood sampling.
On this point, our study does not replicate previous findings showing that patients with WE had low B1 (thiamine) rates (Li et al., 2008) or that 10 patients with severe AUD and liver cirrhosis had lower B1 (thiamine) rates than a control group (62.5 ± 22.2 versus 115 ± 32.5 nM/l) but their cognitive status was not assessed (Tallaksen et al., 1992) . Reversely, our results (mean B1 (thiamine) rates (153 nM/l) are comparable to those of another study showing that B1 (thiamine) rates in 54 AUD patients hospitalized for alcohol detoxification had rates of 161 nM/l [90-337]), although this rate was statistically lower than those of control subjects (mean: 214 nM/l [97-349]) (Rees and Gowing, 2013) . In this last study, as in our work, patients were not selected based on specific cognitive impairment. Another hypothesis to explain why B1 (thiamine) plasmatic level were not low and did not correlated with the MoCA score would be that circulating thiamin rate does not reflect the amount of available thiamine in the brain. Indeed, thiamine deficiency is reported in the literature as the main cause of WKS and is one of the physiopathological hypotheses of cognitive disorders related to alcohol (Cook et al., 1998) . But at the same time, a normal circulating concentration of thiamine diphosphate in the blood does not guarantee that adequate amounts of thiamine are reaching the brain enzymes (α ketoglutarate deshydrogenase complex, transketolase and pyruvate dehydrogenase) that require it. Such an inadequate brain amount can lead to alterations in mitochondrial activity, impairment of oxidative metabolism, decreased energy status and eventually neuronal death (Thomson et al., 2012) . We cannot rule out that a normal plasmatic thiamin rate was associated with low enzymatic activity in some of our patients. The assessment of blood transketolase activity (Gaudral et al., 1987) , which could have been a better assessment, is not part of routine practice in our hospital and was not available here. It is also of note that in our study, only dephosphorylated thiamine was available, while monophosphorylated thiamine and total thiamine were not.
Still, this absence of observed B1 (thiamine) deficiency can be regarded as the result of medical good practices. The prescription of vitamin B1 (thiamine) supplementation is recommended, in the context of heavy alcohol intake, by the World Federation of Societies of Biological Psychiatry Guidelines (Soyka et al., 2008) , or the French Society of Alcohology guidelines (SFA, 2015) . Furthermore, the Royal College Of Physician in United Kingdom proposed to treat all patients in emergency department with any evidence of chronic alcohol misuse and at least one specific symptom, such as ophtalmoplegia or ataxia, with multivitamin supplements (B1 (thiamine), but also B2, B6 (nicotinamide) and vitamin C) in parenteral form for the initial 3-5 days, (Thomson et al., 2002) .
Contrary to previous literature reports ( Thomson et al., 1987) , we did not observe deficiencies in B6, and conversely 58% of our sample had levels above laboratory standards. We can hypothesize that for some patients, this would be the result of a recent outpatient supplementation, as the number of scheduled patients who had a documented supplementation prescription before entry was six, and that B6 (pyridoxine) is often mixed with B1 (thiamine) in several pharmaceutical supplementations. Knowing that it has been described that a significant and prolonged intake of B6 vitamin is associated with sensitive neuropathy, responsible for ataxia, which may not be reversible upon discontinuation of supplementation (Kulkantrakorn, 2014) , this high rate of B6 deserves further explorations.
Contrarily to B1 (thiamine), B3, B6, we observed significant deficiencies in other nutritional and vitamins biomarkers. We observed a higher percentage of patients with albumin rates below the normal range (46.3%) than what was observed in a study assessing nutritional status of inpatients hospitalized for substance-or alcohol used disorders (20.9%) (Ross et al., 2012) . We also observed percentages of patients below the normal range in our sample to be 2-3-fold more numerous than in that previous study for magnesium (11.1% versus 3%) , B9 (28.7% versus 6%), B12 (11% versus 4.5%), C (53.3% versus 7.5%, but only performed in 10 subject from our study, suggesting that this measurement was only performed in patients with clinical signs of malnutrition), or D vitamin (55% versus 6%).
Only the prevalence of Vitamin A below the normal range was less frequent in our sample (7.1%) than in that previous study (19.4%).
The main difference between the two samples is that their inpatient ward received 75% of patients with AUD, while it was the only diagnosed chosen for inclusion in our study. This could either confirm the specific malnutrition profile of patients with AUD compared to other SUD (Jeynes and Gibson, 2017) or be caused by other differences among the two studies. For example, regarding D vitamin, 55% of the patients from our French sample presented a low rate (<20 ng/L), which is close to the prevalence observed in France (42.5%) (Vernay, 2012) . The mean D vitamin rate that we observed: 21.3 ± 10.5 ng/ml was also comparable to the one observed in the French general population 23.0 ng/ml [22.3-23.6 ] (Vernay, 2012) .
Association between nutritional biomarkers and low MoCA scores Here we observed that the lower the BMI of patients, the more likely they were to have a pathological score on the MoCA test. Contrarily to what is observed in normal ageing (Kenny et al., 2013) , we did not observe an association between age and low MoCA scores in our sample. We can hypothesize that the pathophysiological processes causing cognitive impairment in patients with AUD have more impact than ageing, or that we lack the power to detect the cumulative effect of age on cognitive functioning in our patients. Neither neurological signs or symptoms at entry nor nutritional biomarker were statistically associated with low MoCA score in this sample.
Because we did not find any patient with low B1 (thiamine) rate, we could not test its association with low MoCA score, which was a frequent event in our sample (66%). In our sample, a MoCA pathological score was not associated with neither B9 vitamin nor B12 vitamin deficiencies as well, despite previous reports of an association between deficiencies in those vitamins and cognitive impairment in the general population (Reynolds, 2006) . Some studies have shown an association between a low level of D vitamin and a higher risk of cognitive impairment (Lee et al., 2009; Darwish et al., 2015) . Although we did not find a similar association, the high prevalence of deficiency that we found deserves also further explorations.
The rate of low MoCA score that we observed is similar to previous studies in patients with AUD (Alarcon et al., 2015) . It can be regarded as an insight on the continuous pathophysiological process caused by alcohol-related brain damages that will progressively lead to alcohol-related dementia. But patients with severe AUD admitted for inpatient detoxification display several cumulative risk factors for cognitive disorders: low IQ or histories of fetal alcohol spectrum disorders for some of them, continuous alcohol-related neurological toxicity, malnutrition in itself (as seen in patients with anorexia nervosa, cancer, or in geriatric populations), thiamine or other vitamins deficiencies, and on the top of it, withdrawal-related acute neurological toxicity such as in WE. Furthermore, transient cognitive impairment due to withdrawal effects, especially anxiety, or to benzodiazepine remaining effects cannot be ruled out, although the questionnaire was passed at least 24 h after benzodiazepine cessation.
There is to the best of our knowledge, only one previous study assessing nutritional status in 67 inpatients admitted for substance use disorder or AUD-related medical conditions (Ross et al., 2012) , which found a 24% prevalence of malnutrition. Neither B1 (thiamine), B6 (pyridoxine) or B12 (cobalamin) dosage was available in that study. Furthermore, that study did not assess patients cognitive status.
Strength
This study of patients admitted in an acute internal medicine ward specialized in the care of patients with AUD, either during scheduled or unscheduled detoxification, is a good reflection of every day practice in many emergency rooms, internal medicine, and addictology or psychiatry inpatient wards. It is to our knowledge the only study assessing at the same time several nutritional markers, such as BMI or albumin rate, and specific alcohol-related vitamins deficiencies known to be associated with severe neurocognitive disorders (such as B vitamins) which were lacking in other studies (Ross et al., 2012) . The rates of observed malnutrition (8.79%) and acute cognitive impairment at Day 10 (66%) are clinically relevant.
Limitations
The standardized medical file was not always completely filed and some relevant data were missing. As standard laboratory assays were performed, some useful measurements were missing in all patients, especially monophosphorylated thiamin, total thiamin and erythrocyte transketolase activity. Furthermore, other vitamins assays, such as phosphorus or C vitamin were rarely performed, and only in patients with clinical signs of malnutrition. The same limitation applies to the MoCA screening test, and we can hypothesize that patients who were not assessed with this scale had less cognitive impairment. So the prevalence of at-risk patients is probably overestimated. Lastly, we may lack the power to detect clinical factors associated with low MoCA scores, such as the amount of alcohol used. Nevertheless, the association that we observed between low MoCA score and low BMI remains a significant and interesting result, both easy to assess and possibly reversible with appropriate feeding and supplementation programs.
CONCLUSION
This analysis showed that nearly 9% of patients hospitalized for alcohol withdrawal presented a malnutrition defined by a low BMI, and this malnutrition was associated with a low MoCA score. No patient of this sample had low plasmatic thiamin diphosphorylated rate. This result suggests that clinical data (such as weight and height) are more relevant than blood multiple vitamins assessment for the screening of alcohol-related cognitive impairment in AUD patients who are not selected for specific neurocognitive conditions. All AUD patients with low BMI should receive full neuropsychological testing and specific feeding programs should be tested to reduce hospital stay and cognitive impairment in this specific population of patients.
